Our panel, Building the Path Forward: Linkage to Care and Treatment Goals in Hepatitis Delta, at #WHS2026 underscored two urgent priorities: 🔵 Connect patients to care faster – diagnosis without clear pathways to specialist care leaves too many people behind. 🔵 Advance effective treatments – achieving undetectable virus, also known as “target not detected,” remains a critical unmet need. Thank you to our moderator Mark Sonderup and panelists Su Wang and Yasmin Abbas-Ibrahim for an honest, actionable and forward-looking discussion. Learn about our ongoing registrational ECLIPSE Phase 3 program in chronic hepatitis delta ➡️ bit.ly/42Jy0Gw #PatientsAreWaiting #HepatitisDelta
Vir Biotechnology, Inc.
Biotechnology Research
San Francisco, California 38,601 followers
Powering the Immune System to Transform Lives
About us
At Vir Biotechnology, Inc., we leverage the immense potential of the immune system to transform lives by discovering and developing medicines for serious infectious diseases and cancer. We focus on the therapeutic areas in which we believe we can most benefit patients. Our foundational efforts in chronic hepatitis delta are complemented by strategic programs in oncology. Every day, we work with the utmost urgency to deliver potentially transformative medicines for patients. Our pipeline is built on two technology platforms which enable us to rapidly identify, optimize and advance candidates from concepts to the clinic: our next-generation antibody platform and our protease-releasable masking platform in infectious disease and cancer. Explore our full pipeline here: https://bit.ly/3tr7FPm It has come to our attention that there have been various recruitment scams targeting job seekers on LinkedIn. Vir Biotechnology, Inc. is committed to your privacy and will never request sensitive personal information including banking details through email, text message, social media or video software platforms. We also will never request a financial commitment from a candidate as part of the application process. Learn more about Vir Bio's recruiting process: https://bit.ly/461EgJN
- Website
-
http://www.vir.bio
External link for Vir Biotechnology, Inc.
- Industry
- Biotechnology Research
- Company size
- 201-500 employees
- Headquarters
- San Francisco, California
- Type
- Public Company
- Founded
- 2016
Locations
-
Primary
Get directions
1800 Owens St
Suite 900
San Francisco, California 94158, US
-
Get directions
Via Mirasole 1
Bellinzona, Ticino 6500, CH
Employees at Vir Biotechnology, Inc.
Updates
-
Day two at #WHS2026 reinforced a clear message: Persistent gaps in hepatitis delta awareness and treatment need to be closed. Despite the severity of the disease, too few people are receiving effective treatment options. Su Wang #PatientsAreWaiting #HepatitisDelta
-
Join us for our panel at #WHS2026 focused on one of the most urgent challenges in liver health: hepatitis delta virus (HDV). Building the Path Forward will bring together global leaders to discuss the critical need for stronger linkage to care and access to emerging treatments for people living with the most severe form of viral hepatitis. As we advance our registrational ECLIPSE Phase 3 program, we believe achieving undetectable virus, also known as “target not detected,” is the most clinically meaningful efficacy marker for assessing potential HDV treatments. The World Hepatitis Alliance #PatientsAreWaiting #HepatitisDelta
-
👉 #VirBiotechnology will provide a corporate update and report Q1 2026 financial results on Wed., May 6, at 4:30 p.m. ET / 1:30 p.m. PT. Join our investor conference call ➡️ bit.ly/4eCMyyW #Earnings
-
#VirBiotechnology News: We have closed on our global strategic collaboration with Astellas Pharma and look forward to kicking off work together to advance VIR-5500, an investigational PRO‑XTEN® dual‑masked CD3 #TCE targeting #PSMA, for the treatment of prostate cancer. Learn more ➡️ bit.ly/4t9i7F4 *PRO-XTEN® is a trademark of Amunix Pharmaceuticals, Inc., a Sanofi company #PatientsAreWaiting #Immunotherapy #ProstateCancer #mCRPC
-
Ten years ago, we set out to advance transformative treatments for people with high unmet medical needs. From Ebola and COVID‑19 to our ongoing efforts in chronic hepatitis delta and cancer, that commitment continues to drive us. Ringing the Nasdaq Exchange closing bell today is a proud moment for Vir Biotechnology and a celebration of the progress we’ve made together this past decade. To the patients, families, clinical trial participants and our Virites – thank you! *Photos: Nasdaq, Inc./ Vanja Savic #PatientsAreWaiting
-
-
#VirBiotechnology News: We announced dosing of the first patient in our dose-expansion cohorts for VIR-5500, a PSMA-targeting, PRO-XTEN® dual-masked #TCE for metastatic prostate cancer. This milestone builds on encouraging Phase 1 monotherapy data showing favorable safety and promising anti-tumor activity in metastatic castration-resistant prostate cancer #mCRPC. We look forward to continuing this momentum through our strategic Astellas Pharma collaboration to deliver new options for people living with this difficult disease. Learn more in our press release ➡️ bit.ly/48Dh9IP PRO-XTEN® is a trademark of Amunix Pharmaceuticals, Inc., a Sanofi company. #PatientsAreWaiting #Immunotherapy #PSMA
-
We’re excited to ring the Nasdaq Exchange closing bell next week as we kick off Vir Biotechnology’s 10‑year anniversary celebration! This milestone reflects a decade of progress, and we continue to advance treatments for people with high unmet medical needs in chronic hepatitis delta and difficult‑to‑treat solid tumors. Tune in to the livestream on Apr. 14, at 3:45 p.m. ET / 12:45 p.m. PT ➡️ bit.ly/4c41eFU #PatientsAreWaiting #VirBiotechnology
-
“We reviewed profound imaging that showed the effects of VIR-5500 on reducing the cancerous tumors and lesions burdening patients in the trial.” Our CEO Marianne D. De Backer, MSc, PhD, MBA, reflects on early VIR-5500 data, the urgent need in metastatic castration-resistant prostate cancer, and how our strategic collaboration with Astellas Pharma is designed for speed, scale and real impact for people living with this disease. Read the full Stories piece ➡️ bit.ly/47A1jyk #PatientsAreWaiting #mCRPC #Immunotherapy
-
-
Virites recently celebrated #PiDay with a pie-share at #VirBiotechnology, featuring a spread of sweet and savory slices. Here’s to 20-plus pies and 3.14159 – may this tradition go on forever...
-